Immunocore (NASDAQ:IMCR) Price Target Raised to $75.00 at Needham & Company LLC

Immunocore (NASDAQ:IMCR) had its price target raised by Needham & Company LLC from $71.00 to $75.00 in a research note published on Thursday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

IMCR has been the subject of a number of other research reports. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, February 4th. Zacks Research raised Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. Mizuho set a $38.00 price objective on Immunocore in a research report on Thursday, February 19th. Finally, UBS Group set a $55.00 target price on Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.30.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $32.04 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The stock has a 50 day moving average price of $33.55 and a 200 day moving average price of $34.32. The stock has a market capitalization of $1.62 billion, a PE ratio of -45.77 and a beta of 0.78. Immunocore has a 52 week low of $23.15 and a 52 week high of $40.71.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). Immunocore had a negative return on equity of 9.16% and a negative net margin of 8.88%.The company had revenue of $104.48 million for the quarter, compared to the consensus estimate of $145.48 million. During the same quarter in the prior year, the company earned ($0.47) EPS. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. Analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.

Insider Activity at Immunocore

In other news, insider Leger Tina Amber St sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $32,350.00. Following the transaction, the insider directly owned 1,119 shares of the company’s stock, valued at approximately $36,199.65. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David M. Berman sold 5,965 shares of Immunocore stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the sale, the insider owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 19,137 shares of company stock worth $619,082. Corporate insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMCR. Leonteq Securities AG bought a new position in shares of Immunocore in the fourth quarter worth $30,000. GAMMA Investing LLC grew its stake in Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after buying an additional 311 shares in the last quarter. Harbour Investments Inc. increased its holdings in Immunocore by 60.2% in the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Immunocore in the 2nd quarter valued at approximately $42,000. Finally, Arax Advisory Partners lifted its holdings in shares of Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after acquiring an additional 1,042 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

More Immunocore News

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target from $71 to $75 and kept a Buy rating, implying substantial upside vs. the current share price. Benzinga
• Positive Sentiment: Strong product sales and cash runway — KIMMTRAK net sales were $104.5M in Q4 and $400M for FY2025; company ended the year with ~$864.2M in cash, cash equivalents and marketable securities, supporting R&D and runway. Press Release
• Positive Sentiment: Near-term clinical catalysts — Management expects TEBE‑AM enrollment completion 1H2026 with topline as early as 2H2026; multiple PRAME franchise and HIV Phase 1/2 readouts also slated in 2H2026 — potential value-inflecting events. Pipeline Update
• Neutral Sentiment: Full earnings materials available — Management hosted a conference call and released slide deck and transcripts; these provide color on commercialization, trial timelines and cost structure. Earnings Transcript
• Negative Sentiment: Quarterly misses and guidance tone — Q4 EPS of ($0.60) missed consensus (~($0.28)) and revenue of $104.48M materially missed the ~$145M estimate; company cautioned that revenue growth will moderate in 2026, which reduces near-term upside. Earnings Release / Slide Deck

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.